The item has been added to your shopping cart.
Home » SCHERING AND NOVARTIS COLLABORATE ON POSSIBLE CANCER BLOCKBUSTER
SCHERING AND NOVARTIS COLLABORATE ON POSSIBLE CANCER BLOCKBUSTER
Switzerland-based drug major Novartis and Germany's Schering AG are jointly conducting development activity on a new anticancer compound known as PTK/ZK. The two companies claim the drug, which reportedly blocks blood flow to tumours, could earn sales of some EUR2bn (US$2.7bn).
Studies currently involve examinations into the drug's effectiveness against intestinal cancer, although the technology could be transferred to other therapeutic areas in oncology.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct